Awen M Gallimore

List of Publications by Year
in descending order

114 papers	8,173 citations	50276 46 h-index	48315 88 g-index
115 all docs	115 docs citations	115 times ranked	10793 citing authors

#	Article	IF	Citations
1	HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Medicine, 1995, 1, 59-64.	30.7	771
2	Induction and Exhaustion of Lymphocytic Choriomeningitis Virusâ€“specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class Iâ€“Peptide Complexes. Journal of Experimental Medicine, 1998, 187, 1383-1393.	8.5	688
3	Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine, 2000, 19, 764-778.	3.8	329
4	OX40-Deficient Mice Are Defective in Th Cell Proliferation but Are Competent in Generating B Cell and CTL Responses after Virus Infection. Immunity, 1999, 11, 699-708.	14.3	297
5	Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nature Medicine, 2002, 8, 373-378.	30.7	276
6	Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. European Journal of Immunology, 2002, 32, 3267-3275.	2.9	257
7	Protective Immunity Does Not Correlate with the Hierarchy of â€‰Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides. Journal of Experimental Medicine, 1998, 187, 1647-b-1657.	8.5	252
8	Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Medicine, 1995, 1, 1167-1173.	30.7	200
9	Inducible Costimulator Protein (Icos) Controls T Helper Cell Subset Polarization after Virus and Parasite Infection. Journal of Experimental Medicine, 2000, 192, 53-62.	8.5	192
10	CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer. PLoS ONE, 2006, 1, e129.	2.5	183
11	Complement: central to innate immunity and bridging to adaptive responses. Immunology Letters, 2005, 97, 171-179.	2.5	178
12	Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?. Frontiers in Immunology, 2017, 8, 1830.	4.8	168
13	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunology, Immunotherapy, 2015, 64, 1271-1286.	4.2	161
14	MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. European Journal of Immunology, 2000, 30, 3623-3633.	2.9	148
15	Interleukinâ€6 limits influenzaâ€induced inflammation and protects against fatal lung pathology. European Journal of Immunology, 2013, 43, 2613-2625.	2.9	143
16	Developmental Regulation of Lck Targeting to the CD8 Coreceptor Controls Signaling in Naive and Memory T Cells. Journal of Experimental Medicine, 1999, 189, 1521-1530.	8.5	138
17	TCR affinity and negative regulation limit autoimmunity. Nature Medicine, 2004, 10, 1234-1239.	30.7	138
18	Suppression of tumour-specific CD4⁺T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut, 2012, 61, 1163-1171.	12.1	127

#	Article	IF	Citations
19	Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunity, 2002, 2, 1.	3.2	125
20	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 6771-6780.	7.0	114
21	Analysis of the T-Cell Receptor Repertoires of Tumor-Infiltrating Conventional and Regulatory T Cells Reveals No Evidence for Conversion in Carcinogen-Induced Tumors. Cancer Research, 2011, 71, 736-746.	0.9	112
22	Holding T cells in check â€“ a new role for complement regulators?. Trends in Immunology, 2006, 27, 102-108.	6.8	100
23	T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion. Cancer Research, 2012, 72, 5473-5482.	0.9	97
24	Immunodominance of an Antiviral Cytotoxic T Cell Response Is Shaped by the Kinetics of Viral Protein Expression. Journal of Immunology, 2003, 171, 5415-5422.	0.8	96
25	Oncogenic Properties of Apoptotic Tumor Cells in Aggressive B Cell Lymphoma. Current Biology, 2015, 25, 577-588.	3.9	96
26	Regulatory T cells and tumour immunity â€“ observations in mice and men. Immunology, 2008, 123, 157-163.	4.4	94
27	Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. Journal of Immunology, 2005, 175, 7264-7273.	0.8	89
28	Interleukin-6 Is Crucial for Recall of Influenza-Specific Memory CD4+ T Cells. PLoS Pathogens, 2008, 4, e1000006.	4.7	89
29	The MHC E locus in macaques is polymorphic and is conserved between macaques and humans. Immunogenetics, 1995, 41, 59-68.	2.4	86
30	Functionally distinct CD8+ memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression. European Journal of Immunology, 2000, 30, 1823-1829.	2.9	82
31	Treg Depletion Licenses T Cellâ€“Driven HEV Neogenesis and Promotes Tumor Destruction. Cancer Immunology Research, 2017, 5, 1005-1015.	3.4	78
32	Regulation of tumour immunity by CD25+ T cells. Immunology, 2002, 107, 5-9.	4.4	77
33	Role of Immunoproteasomes in Cross-Presentation. Journal of Immunology, 2006, 177, 983-990.	0.8	74
34	The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology, 2019, 19, 98.	2.0	72
35	Deletion of the CD4 silencer element supports a stochastic mechanism of thymocyte lineage commitment. Nature Immunology, 2001, 2, 1167-1173.	14.5	70
36	Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells. Frontiers in Immunology, 2013, 4, 197.	4.8	70

#	Article	IF	Citations
37	Hierarchies of antigen-specific cytotoxic T-cell responses. Immunological Reviews, 1998, 164, 29-32.	6.0	67
38	Cutting Edge: Murine CD59a Modulates Antiviral CD4+ T Cell Activity in a Complement-Independent Manner. Journal of Immunology, 2005, 175, 7098-7102.	0.8	67
39	High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology, 2015, 4, e974374.	4.6	60
40	Neutrophils Recruited by IL-22 in Peripheral Tissues Function as TRAIL-Dependent Antiviral Effectors against MCMV. Cell Host and Microbe, 2014, 15, 471-483.	11.0	58
41	Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. European Journal of Immunology, 2001, 31, 450-458.	2.9	56
42	A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. European Journal of Immunology, 1998, 28, 3301-3311.	2.9	54
43	The paradox of NKp46⁺natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon Î± treatment. Gut, 2014, 63, 515-524.	12.1	54
44	Tâ€cell modulation by cyclophosphamide for tumour therapy. Immunology, 2018, 154, 62-68.	4.4	53
45	Regulating the immune response to tumours. Advanced Drug Delivery Reviews, 2006, 58, 948-961.	13.7	51
46	Synergistic targeting of breast cancer stemâ€like cells by human Î³Î´ T cells and CD8⁺ T cells. Immunology and Cell Biology, 2017, 95, 620-629.	2.3	51
47	Effect of Modified Vaccinia Ankaraâ€“5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, e172579.	7.1	51
48	L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 1321.	4.8	50
49	The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺and CD8⁺Tâ€cell immunity. FASEB Journal, 2012, 26, 3575-3586.	0.5	48
50	Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology, 2010, 131, 583-592.	4.4	47
51	Epithelial Barriers, Microbiota, and Colorectal Cancer. New England Journal of Medicine, 2013, 368, 282-284.	27.0	47
52	CD59 Blockade Enhances Antigen-Specific CD4+ T Cell Responses in Humans: A New Target for Cancer Immunotherapy?. Journal of Immunology, 2009, 182, 5203-5207.	0.8	46
53	Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNÎ³-dependent iNOS expression in the vasculature of healthy mice. Blood, 2008, 111, 5187-5194.	1.4	43
54	Hyperactive gp130/STAT3â€driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. International Journal of Cancer, 2018, 143, 167-178.	5.1	43

#	Article	IF	Citations
55	Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax, 2011, 66, 368-374.	5.6	39
56	CD62L (L-Selectin) Down-Regulation Does Not Affect Memory T Cell Distribution but Failure to Shed Compromises Anti-Viral Immunity. Journal of Immunology, 2008, 180, 198-206.	0.8	38
57	Type I Interferon (IFNÎ±) Acts Directly on Human Memory CD4+T Cells Altering Their Response to Antigen. Journal of Immunology, 2009, 183, 2915-2920.	0.8	38
58	Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications, 2012, 3, 665.	12.8	36
59	Anti-CD8 Antibodies Can Trigger CD8+ T Cell Effector Function in the Absence of TCR Engagement and Improve Peptideâ€“MHCI Tetramer Staining. Journal of Immunology, 2011, 187, 654-663.	0.8	34
60	CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms. European Journal of Immunology, 2007, 37, 1266-1274.	2.9	31
61	Delineating Immune-Mediated Mechanisms Underlying Hair Follicle Destruction in the Mouse Mutant Defolliculated. Journal of Investigative Dermatology, 2011, 131, 572-579.	0.7	31
62	Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology, 2007, 37, 798-806.	2.9	30
63	Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell, 2002, 2, 315-322.	16.8	29
64	CD25+ regulatory T cells and tumor immunity. Immunology Letters, 2003, 85, 141-143.	2.5	29
65	The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity. Trends in Cancer, 2021, 7, 214-225.	7.4	28
66	Cytotoxic T cellsâ€"protection from disease progressionâ€"protection from infection. Immunology Letters, 1996, 51, 125-128.	2.5	27
67	Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1999, 29, 2213-2222.	2.9	27
68	Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation, 2018, 128, 1569-1580.	8.2	27
69	Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances, 2022, 2, ltab025.	3.0	26
70	Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. European Journal of Immunology, 2007, 37, 758-767.	2.9	25
71	The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. Immunology, 2003, 109, 68-75.	4.4	24
72	Mbd2 enables tumourigenesis within the intestine while preventing tumourâ€promoting inflammation. Journal of Pathology, 2018, 245, 270-282.	4.5	24

#	Article	IF	Citations
73	Exogenous Peptides Delivered by Ricin Require Processing by Signal Peptidase for Transporter Associated with Antigen Processing-Independent MHC Class I-Restricted Presentation. Journal of Immunology, 2002, 169, 99-107.	0.8	23
74	Defining High Endothelial Venules and Tertiary Lymphoid Structures in Cancer. Methods in Molecular Biology, 2018, 1845, 99-118.	0.9	23
75	Enhanced antitumor immunity through sequential targeting of PI3KÎ´ and LAG3. , 2020, 8, e000693.		22
76	Whole bloodâ€based measurement of SARSâ€CoVâ€2â€specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solidâ€organ cancers. Immunology, 2022, 165, 250-259.	4.4	21
77	T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology, 2021, 2, iqaa007.	2.8	19
78	The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leaderâ€"derived T cell epitope. Molecular Immunology, 1998, 35, 581-591.	2.2	17
79	T cell subsets and colorectal cancer: Discerning the good from the bad. Cellular Immunology, 2012, 279, 21-24.	3.0	17
80	CD200 Receptor Restriction of Myeloid Cell Responses Antagonizes Antiviral Immunity and Facilitates Cytomegalovirus Persistence within Mucosal Tissue. PLoS Pathogens, 2015, 11, e1004641.	4.7	16
81	Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection. Cancer Immunology Research, 2020, 8, 1520-1531.	3.4	16
82	Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget, 2015, 6, 24649-24659.	1.8	16
83	Rapid early innate control of hepatitis C virus during IFN â€Î± treatment compromises adaptive CD 4 + T â€cell immunity. European Journal of Immunology, 2012, 42, 2383-2394.	2.9	15
84	Escalating Regulation of 5T4-Specific IFN-Î³+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy. Cancer Immunology Research, 2013, 1, 416-425.	3.4	15
85	Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. Journal of Immunological Methods, 2015, 424, 131-135.	1.4	15
86	Assessing the Prognostic Value of Preoperative Carcinoembryonic Antigen-Specific T-Cell Responses in Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	14
87	Molecular characterization of HLA class II binding to the LAGâ€3 T cell coâ€inhibitory receptor. European Journal of Immunology, 2021, 51, 331-341.	2.9	13
88	Antigen Specificity Determines the Pro- or Antitumoral Nature of CD8+ T Cells. Journal of Immunology, 2010, 184, 607-614.	0.8	12
89	Cytotoxic T lymphocyte epitopes shared between HIVâ€1, HIVâ€2, and SIV. Journal of Medical Primatology, 1993, 22, 119-123.	0.6	12
90	The Influence of CD25+ Cells on the Generation of Immunity to Tumour Cell Lines in Mice. Novartis Foundation Symposium, 2008, , 149-157.	1.1	11

#	Article	IF	Citations
91	CD4+ T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical Features. Cell Reports, 2020, 32, 107885.	6.4	11
92	Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry, 2019, 294, 20246-20258.	3.4	10
93	The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy, 2019, 68, 247-256.	4.2	10
94	A distinct chemokine axis does not account for enrichment of Foxp3⁺Â<scp>CD</scp>4⁺ T cells in carcinogenâ€induced fibrosarcomas. Immunology, 2015, 145, 94-104.	4.4	9
95	Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy, 2020, 69, 2063-2073.	4.2	9
96	T-Cell Costimulation. New England Journal of Medicine, 2006, 355, 2594-2595.	27.0	8
97	Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. , 2002, 32, 3267.		8
98	Exploiting ECM remodelling to promote immune-mediated tumour destruction. Current Opinion in Immunology, 2022, 74, 32-38.	5.5	8
99	Progression of carcinogenâ€induced fibrosarcomas is associated with the accumulation of naÃ¯ve CD4+ T cells via blood vessels and lymphatics. International Journal of Cancer, 2014, 134, 2156-2167.	5.1	7
100	Sequential targeting of PI3KÎ´ and LAG3 as an effective anti-cancer approach. British Journal of Cancer, 2021, 125, 467-469.	6.4	7
101	Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology, 2021, 2, .	2.8	7
102	Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. Immunology, 2021, 163, 389-398.	4.4	5
103	High endothelial venules. OncoImmunology, 2013, 2, e24272.	4.6	4
104	Limited in vivo reactivity of polyclonal effector cytotoxic T cells towards altered peptide ligands. Microbes and Infection, 2005, 7, 729-737.	1.9	3
105	Avidity of influenzaâ€specific memory <scp>CD</scp>8⁺<scp>T</scp>â€cell populations decays over time compromising antiviral immunity. European Journal of Immunology, 2012, 42, 3235-3242.	2.9	3
106	Complementâ€induced protection: an explanation for the limitations of cellâ€based tumour immunotherapies. Immunology and Cell Biology, 2012, 90, 869-871.	2.3	3
107	Rapid innate control of antigen abrogates adaptive immunity. Immunology, 2013, 138, 293-297.	4.4	2
108	Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer, 2021, 124, 1552-1555.	6.4	2

#	Article	IF	Citations
109	Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. European Journal of Immunology, 2001, 31, 450-458.	2.9	1
110	MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology, 2017, 35, 154-154.	1.6	1
111	Setting the threshold for extraâ€thymic differentiation of Foxp3⁺ Tregs: TGFâ€Î²â€dependent and Tâ€cell autonomous. European Journal of Immunology, 2011, 41, 1218-1220.	2.9	0
112	Hunting for clues. OncoImmunology, 2012, 1, 1163-1164.	4.6	0
113	Flow cytometry makes all the difference. Journal of Hepatology, 2013, 59, 909-910.	3.7	0
114	Tumor-Associated High Endothelial Venules: Inroads Enabling Immune Control of Cancer Progression. Cancer Immunology Research, 2022, 10, 371-371.	3.4	0